Q2 2026 13F · SEC CIK 1469336

Empery Asset Management, LP

Hedge fundFiled 2026-08-11 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $86.5M
Reported positions: 32
Holdings vs S&P 500, 3 yrs: —
Assets under management: $262.5M

Empery Asset Management, LP is a hedge fund that reported 32 positions worth $86.5M in its Q2 2026 13F, filed 2026-08-11. Its largest holdings were X4 Pharmaceuticals Inc (XFOR, 37.4%), Empery Digital Inc (EMPD, 12.1%), Nervgen Pharma Corp (NGEN, 9.5%).

Empery Asset Management, LP holdings all 32 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Empery Asset Management, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
XFORX4 Pharmaceuticals Inc	37.4%	44.5%	6,930,591	-22.5%	$32.4M
EMPDEmpery Digital Inc	12.1%	14.9%	2,930,345	+0.0%	$10.4M
NGENNervgen Pharma Corp	9.5%	New	4,000,000	—	$8.2M
DTILPrecision Biosciences Inc	7.1%	13.0%	776,093	-60.6%	$6.1M
CLNNClene Inc	6.5%	New	916,532	—	$5.6M
ANVSAnnovis Bio Inc	5.2%	New	2,401,476	—	$4.5M
LTRNLantern Pharma Inc	4.1%	New	842,669	—	$3.5M
AMCAmc Entmt Hldgs Inc	3.8%	New	1,714,043	—	$3.3M
TNYATenaya Therapeutics Inc	3.3%	3.6%	3,863,115	-9.9%	$2.9M
YDDLOne and One Green Technologi	1.8%	New	761,706	—	$1.5M
CYNCyngn Inc	1.5%	1.9%	927,059	-3.2%	$1.3M
VENUVenu Hldg Corp	1.3%	4.0%	512,818	-49.1%	$1.2M
GLNDWGreenland Energy Co	1.0%	New	1,000,000	—	$850K
URGUr-Energy Inc	1.0%	1.1%	620,136	+0.0%	$843K
MSLESatellos Bioscience Inc	1.0%	1.6%	107,100	-53.5%	$833K
JAGUJaguar Uranium Corp	0.9%	1.6%	487,500	+0.0%	$814K
CLRBCellectar Biosciences Inc	0.6%	New	189,605	—	$527K
SCYXScynexis Inc	0.6%	New	126,451	—	$515K
RNTXRein Therapeutics Inc	0.4%	New	370,834	—	$386K
BTCTBtc Digital Ltd	0.3%	New	350,877	—	$289K
BCTXLBriacell Therapeutics Corp	0.3%	0.4%	300,000	+0.0%	$267K
MTEKWMaris Tech Ltd	0.1%	0.1%	297,600	+0.0%	$58K
PRZOParazero Technologies Ltd	0.1%	0.3%	113,771	-59.7%	$55K
DUKRWDuke Robotics Corp	0.1%	New	35,000	—	$45K
NTRBWNutriband Inc	0.0%	0.1%	40,218	+0.0%	$40K
RTACWRenatus Tactical Acquis	0.0%	0.0%	50,000	+0.0%	$38K
84757T113Spectral Ai Inc	0.0%	0.0%	33,336	+0.0%	$19K
NEXRWNexera Technologies Ltd	0.0%	0.0%	360,577	+0.0%	$10K
CEADWCea Industries Inc	0.0%	0.0%	500,000	+0.0%	$9K
G3302D111Fgi Industries Ltd	0.0%	0.0%	83,928	+0.0%	$8K
NRSNWNeurosense Therapeutics Ltd	0.0%	0.0%	100,402	+0.0%	$6K
NXGLWNexgel Inc	0.0%	0.0%	90,000	+0.0%	$3K

What Empery Asset Management, LP bought and sold in Q2 2026, against Q1 2026.

New positions

NGEN Nervgen Pharma Corp9.5% of 13F
CLNN Clene Inc6.5% of 13F
ANVS Annovis Bio Inc5.2% of 13F
LTRN Lantern Pharma Inc4.1% of 13F
AMC Amc Entmt Hldgs Inc3.8% of 13F
YDDL One and One Green Technologi1.8% of 13F
GLNDW Greenland Energy Co1.0% of 13F
CLRB Cellectar Biosciences Inc0.6% of 13F

Added to

No position grew by more than 5%.

Reduced

DTIL Precision Biosciences Inc-60.6% shares
PRZO Parazero Technologies Ltd-59.7% shares
MSLE Satellos Bioscience Inc-53.5% shares
VENU Venu Hldg Corp-49.1% shares
XFOR X4 Pharmaceuticals Inc-22.5% shares
TNYA Tenaya Therapeutics Inc-9.9% shares

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$86.5M	32
Q1 2026	$83.0M	32
Q4 2025	$113.4M	31
Q3 2022	$16.8M	88
Q2 2022	$18.5M	75
Q1 2022	$21.3M	77
Q4 2021	$47.9M	70

Questions about Empery Asset Management, LP's portfolio

What stocks does Empery Asset Management, LP own?

Empery Asset Management, LP's latest 13F, for Q2 2026 and filed Aug 11, 2026, lists 32 positions worth $86.5M. The largest are X4 Pharmaceuticals Inc (XFOR) at 37.4%, Empery Digital Inc (EMPD) at 12.1%, Nervgen Pharma Corp (NGEN) at 9.5%, Precision Biosciences Inc (DTIL) at 7.1% and Clene Inc (CLNN) at 6.5%.

What did Empery Asset Management, LP buy last quarter?

In Q2 2026, Empery Asset Management, LP added a new position in Nervgen Pharma Corp (NGEN), a new position in Clene Inc (CLNN), a new position in Annovis Bio Inc (ANVS), a new position in Lantern Pharma Inc (LTRN) and a new position in Amc Entmt Hldgs Inc (AMC), compared with its Q1 2026 filing.

What did Empery Asset Management, LP sell last quarter?

In Q2 2026, Empery Asset Management, LP sold all of Imperial Pete Inc Com New (IMPP), sold all of Big Sky Industrial Inc (BSIN), sold all of Scynexis Inc (SCYX), sold all of Critical Metals Corp (CRML), sold all of Promis Neurosciences Inc (PMN), Precision Biosciences Inc (DTIL) (-60.6% shares), Parazero Technologies Ltd (PRZO) (-59.7% shares) and Satellos Bioscience Inc (MSLE) (-53.5% shares), compared with its Q1 2026 filing.

When is Empery Asset Management, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Empery Asset Management, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Empery Asset Management, LP manage?

Empery Asset Management, LP reported $262.5M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $86.5M.